Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

Prostate Cancer: Sounding An Early Alarm

Developments to Watch


Prostate cancer, the most common cancer in men over 50, kills 30,000 a year. One reason is that men don't usually get checked for the disease unless they experience symptoms, such as painful urination. By then, the cancer has spread beyond the prostate in 70% of patients. According to a study in The New England Journal of Medicine, a blood test may soon make it possible to detect the cancer much earlier.

The study, conducted by researchers at Barnes Hospital and Washington University School of Medicine in St. Louis, involved a 10-minute test that measures bloodstream levels of prostate-specific antigen (PSA), a protein produced by the prostate gland. Because PSA levels seem to increase as the disease advances, the test can predict more accurately and earlier which men have the cancer than can rectal exams or ultrasound, the usual diagnostic tests. Without the blood test, up to 40% of the cancers found during the study would have been missed. In patients with mildly elevated PSA levels who had cancer, the disease was localized and therefore curable.

"We'd like to see all men, beginning at age 50, have their PSA levels checked annually as a screening test for prostate cancer," says Dr. William J. Catalona, head of urologic surgery at Washington University.EDITED BY WILLIAM D. MARBACH

blog comments powered by Disqus